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ment for HIV-associated progressive multifocal
leukoencephalopathy
HIV-associated progressive multi-focal leukoencephalopathy
(PML) is a severe neurodegenerative disorder that leads to
disability and death from fulminant damage to cerebral
white matter. PML is caused by human polyoma JC virus,
an almost ubiquitous virus normally kept in check by the
immune system.1 PML had been common prior to the advent
of highly active anti-retroviral therapy (HAART), and now
some cases are being seen in the context of HAART failure2
and also immune reconstitution syndrome, where a patient’s
HAART-restored immune system attacks brain tissue.3 Cur-
rently available treatments such as interferon are often
ineffective4 and new approaches are needed. I propose
the hypothesis that thiazolidinediones (TZs) such as piogli-
tazone and rosiglitazone, currently used for treatment of
type II diabetes, could potentially slow the course of PML and
under the best of circumstances, induce a complete remis-
sion.
Both basic science and clinical data lend support to the
above idea. TZs have pleiotropic neuroprotective effects
that can be demonstrated in several different animalmodels
of neurodegeneration.5 Neuroprotective effects are
believed to be through anti-inflammatory mechanisms
mediated by the peroxisome-activated gamma receptor.5
TZ stimulation of the peroxisome-activated gamma receptor
suppresses a multitude of inflammatory cytokines both in
cultured cells and in vivo in animal models.5—7 Furthermore,
pioglitazone has been shown to reduce activation of Tlymphocytes from patients with multiple sclerosis,8 and
there is a published case report from 2004 of a 44-year-
old woman with severe progressive multiple sclerosis, com-
plicated by quadriparesis, ataxia, fatigue and cognitive
decline, who had a significant clinical remission taking
pioglitazone.5 Large scale clinical trials with multiple
sclerosis patients are undoubtedly underway now. Given
that multiple sclerosis and PML are both demyelinating
inflammation of the cerebral white matter, it would be
logical to similarly initiate clinical trials in patients with
HIV-associated PML. The trials could be either large rando-
mized placebo controlled studies or ‘n of 1’ longitudinal
studies like that for the patient with multiple sclerosis. TZs
already show promise as a treatment for HAART-associated
lipodystrophy9,10 so from an ethical standpoint potential
benefits to patients would certainly justify open-label ‘n
of 1’ studies, if they are done by HIV specialists who
would insure no deleterious drug interactions with HAART
medications.
In conclusion, potential benefits of TZs for HIV-associated
PML warrant further investigation.
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doi:10.1016/j.ijid.2006.09.012Figure 1 Axial, FLAIR image demonstrates diffuse, ill-defined
hyperintense areas in the periventricular white matter, without
significant mass effect.A case of human immunodeficiency virus infec-
tion disclosed by cytomegalovirus encephalitis
We report herein an unusual case of human immunodefi-
ciency virus (HIV) infection disclosed by hypothalamic ame-
norrhea and cytomegalovirus (CMV) encephalitis.
One year before admission the patient presented with
amenorrhea, mild gait unsteadiness, anorexia, easy fatig-
ability andweight loss (10 kg). Eight months before admission
she had visited a gynecologist who prescribed hormonal
therapy for amenorrhea, without any effect. Laboratory tests
performed at the time showed anemia with increased serum
ferritin. At the same time, the patient visited a psychiatrist,
who prescribed an antidepressant. Due to the unresponsive-
ness of the patient’s symptoms to the antidepressant treat-
ment, a head CTscan was performed, which was normal. The
patient was admitted to the endocrinology department for
investigation of amenorrhea.
Hormonal evaluation on admission showed normal serum
luteinizing hormone (LH: 2.18 mIU/ml) and follicle-stimulat-
ing hormone (FSH: 2.69 mIU/ml) concentrations, and an
exaggerated LH (40.93 mIU/ml) and FSH (24.93 mIU/ml)
activity after gonadotropin-releasing hormone (GnRH)
administration.
The patient was diagnosed as having hypothalamic ame-
norrhea and hormonal replacement therapy was prescribed.
On neurological examination the patient was alert, but had a
low score (23/30) onmini-mental status examination (MMSE).
She presented involuntary choreiform movements of the
upper and lower extremities and was unable to perform
the tandem walking test. She presented dysdiadochokinesia
and the deep tendon reflexes were symmetrically increased.
A magnetic resonance imaging (MRI) examination of the brain
was performed and demonstrated diffuse hyperintense areas
on T2-weighted sequences in the periventricular white mat-ter, as well as in the centrum semiovale bilaterally. The
abnormal areas were located mainly in the occipital lobes
and there was no evidence of mass effect or contrast
enhancement (Figure 1); the patient refused any further
investigation and she was discharged.
Three months later she was re-admitted to the neurology
department due to deteriorating gait unsteadiness. Her MMSE
